Arcturus therapeutics announces initiation of dosing in phase 2 multiple ascending dose studies for cystic fibrosis (cf) and ornithine transcarbamylase (otc) deficiency

San diego--(business wire)---- $arct #clinicaltrial--arcturus therapeutics holdings inc. (the “company”, “arcturus”, nasdaq: arct), a commercial messenger rna medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the first cf and otc deficiency participants initiated dosing in december 2024, in the company's phase 2 multiple ascending dose studies. each participant in the phase 2 cf study (nct06747858) is expected t.
CF Ratings Summary
CF Quant Ranking